Insider Selling: Thermo Fisher Scientific Inc. (NYSE:TMO) Director Sells $1,294,858.84 in Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) Director Jim P. Manzi sold 3,218 shares of the business’s stock in a transaction that occurred on Friday, July 24th. The stock was sold at an average price of $402.38, for a total transaction of $1,294,858.84. Following the completion of the transaction, the director now owns 21,803 shares of the company’s stock, valued at $8,773,091.14. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

NYSE TMO opened at $410.56 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 2.02 and a current ratio of 2.62. The firm’s 50 day moving average price is $372.71 and its 200-day moving average price is $334.97. Thermo Fisher Scientific Inc. has a 52-week low of $250.21 and a 52-week high of $420.99. The company has a market cap of $161.98 billion, a PE ratio of 44.43, a P/E/G ratio of 1.82 and a beta of 1.04.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 22nd. The medical research company reported $3.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.22. Thermo Fisher Scientific had a net margin of 14.12% and a return on equity of 18.18%. The firm had revenue of $6.92 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the firm earned $3.04 earnings per share. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 14.95 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.22 dividend. The ex-dividend date of this dividend is Monday, September 14th. This represents a $0.88 annualized dividend and a yield of 0.21%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 7.13%.

A number of equities research analysts have recently issued reports on TMO shares. Cowen reissued a “buy” rating and set a $380.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Needham & Company LLC increased their price objective on shares of Thermo Fisher Scientific from $415.00 to $468.00 and gave the company a “buy” rating in a report on Thursday, July 23rd. Citigroup upped their target price on shares of Thermo Fisher Scientific from $390.00 to $471.00 and gave the company a “buy” rating in a research report on Thursday, July 23rd. UBS Group increased their price objective on shares of Thermo Fisher Scientific from $385.00 to $440.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Finally, Argus increased their price objective on shares of Thermo Fisher Scientific from $370.00 to $450.00 in a research report on Monday. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $420.50.

A number of institutional investors and hedge funds have recently made changes to their positions in TMO. Quadrant Capital Group LLC boosted its stake in Thermo Fisher Scientific by 21.6% in the fourth quarter. Quadrant Capital Group LLC now owns 6,068 shares of the medical research company’s stock valued at $1,931,000 after acquiring an additional 1,078 shares in the last quarter. Equitable Holdings Inc. acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $423,000. LMR Partners LLP acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $314,000. 1832 Asset Management L.P. boosted its stake in Thermo Fisher Scientific by 258.8% in the fourth quarter. 1832 Asset Management L.P. now owns 280,902 shares of the medical research company’s stock valued at $91,720,000 after acquiring an additional 202,603 shares in the last quarter. Finally, Brooktree Capital Management acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $353,000. Institutional investors own 87.51% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Recommended Story: What Every Investor Needs to Understand About Secondary Public Offerings

Insider Buying and Selling by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.